520 related articles for article (PubMed ID: 25582824)
1. Enhancing antitumor efficacy of chimeric antigen receptor T cells through constitutive CD40L expression.
Curran KJ; Seinstra BA; Nikhamin Y; Yeh R; Usachenko Y; van Leeuwen DG; Purdon T; Pegram HJ; Brentjens RJ
Mol Ther; 2015 Apr; 23(4):769-78. PubMed ID: 25582824
[TBL] [Abstract][Full Text] [Related]
2. CD40 Ligand-Modified Chimeric Antigen Receptor T Cells Enhance Antitumor Function by Eliciting an Endogenous Antitumor Response.
Kuhn NF; Purdon TJ; van Leeuwen DG; Lopez AV; Curran KJ; Daniyan AF; Brentjens RJ
Cancer Cell; 2019 Mar; 35(3):473-488.e6. PubMed ID: 30889381
[TBL] [Abstract][Full Text] [Related]
3. Adenovirus-mediated CD40 ligand gene-engineered dendritic cells elicit enhanced CD8(+) cytotoxic T-cell activation and antitumor immunity.
Liu Y; Zhang X; Zhang W; Chen Z; Chan T; Ali K; Jia Z; Xiang J
Cancer Gene Ther; 2002 Feb; 9(2):202-8. PubMed ID: 11857039
[TBL] [Abstract][Full Text] [Related]
4. Complete rejection of a T-cell lymphoma due to synergism of T-cell receptor costimulatory molecules, CD80, CD40L, and CD40.
Ruybal P; Gravisaco MJ; Barcala V; Escalada A; Di Sciullo P; Waldner C; Mongini C
Vaccine; 2008 Jan; 26(5):697-705. PubMed ID: 18155328
[TBL] [Abstract][Full Text] [Related]
5. Genetically targeted T cells eradicate systemic acute lymphoblastic leukemia xenografts.
Brentjens RJ; Santos E; Nikhamin Y; Yeh R; Matsushita M; La Perle K; Quintás-Cardama A; Larson SM; Sadelain M
Clin Cancer Res; 2007 Sep; 13(18 Pt 1):5426-35. PubMed ID: 17855649
[TBL] [Abstract][Full Text] [Related]
6. Dendritic and tumor cell fusions transduced with adenovirus encoding CD40L eradicate B-cell lymphoma and induce a Th17-type response.
Alvarez E; Moga E; Barquinero J; Sierra J; Briones J
Gene Ther; 2010 Apr; 17(4):469-77. PubMed ID: 20010627
[TBL] [Abstract][Full Text] [Related]
7. Expression patterns of costimulatory molecules on cells derived from human hematological malignancies.
Zheng Z; Takahashi M; Aoki S; Toba K; Liu A; Osman Y; Takahashi H; Tsukada N; Suzuki N; Nikkuni K; Furukawa T; Koike T; Aizawa Y
J Exp Clin Cancer Res; 1998 Sep; 17(3):251-8. PubMed ID: 9894758
[TBL] [Abstract][Full Text] [Related]
8. CD28 costimulation provided through a CD19-specific chimeric antigen receptor enhances in vivo persistence and antitumor efficacy of adoptively transferred T cells.
Kowolik CM; Topp MS; Gonzalez S; Pfeiffer T; Olivares S; Gonzalez N; Smith DD; Forman SJ; Jensen MC; Cooper LJ
Cancer Res; 2006 Nov; 66(22):10995-1004. PubMed ID: 17108138
[TBL] [Abstract][Full Text] [Related]
9. T-cell-dependent antitumor effects produced by CD40 ligand expressed on mouse lung carcinoma cells are linked with the maturation of dendritic cells and secretion of a variety of cytokines.
Tada Y; O-Wang J; Yu L; Shimozato O; Wang YQ; Takiguchi Y; Tatsumi K; Kuriyama T; Takenaga K; Sakiyama S; Tagawa M
Cancer Gene Ther; 2003 Jun; 10(6):451-6. PubMed ID: 12768190
[TBL] [Abstract][Full Text] [Related]
10. Therapeutic vaccination against murine lymphoma by intratumoral injection of recombinant fowlpox virus encoding CD40 ligand.
Liu A; Guardino A; Chinsangaram L; Goldstein MJ; Panicali D; Levy R
Cancer Res; 2007 Jul; 67(14):7037-44. PubMed ID: 17638917
[TBL] [Abstract][Full Text] [Related]
11. Upregulation of adhesion molecules on leukemia targets improves the efficacy of cytotoxic T cells transduced with chimeric anti-CD19 receptor.
Laurin D; Marin V; Biagi E; Pizzitola I; Agostoni V; Gallot G; Vié H; Jacob MC; Chaperot L; Aspord C; Plumas J
J Immunother; 2013 Apr; 36(3):181-9. PubMed ID: 23502765
[TBL] [Abstract][Full Text] [Related]
12. Coexpression of CD40L and CD70 by semiallogenic tumor cells induces anti-tumor immunity.
Cormary C; Hiver E; Mariamé B; Favre G; Tilkin-Mariamé AF
Cancer Gene Ther; 2005 Dec; 12(12):963-72. PubMed ID: 15956983
[TBL] [Abstract][Full Text] [Related]
13. Activation of B cells using Schneider 2 cells expressing CD40 ligand for the enhancement of antigen presentation in vitro.
Yoon SH; Cho HI; Kim TG
Exp Mol Med; 2005 Dec; 37(6):567-74. PubMed ID: 16391518
[TBL] [Abstract][Full Text] [Related]
14. Enhancing the T-cell stimulatory capacity of human dendritic cells by co-electroporation with CD40L, CD70 and constitutively active TLR4 encoding mRNA.
Bonehill A; Tuyaerts S; Van Nuffel AM; Heirman C; Bos TJ; Fostier K; Neyns B; Thielemans K
Mol Ther; 2008 Jun; 16(6):1170-80. PubMed ID: 18431362
[TBL] [Abstract][Full Text] [Related]
15. CD40 signalling induces IL-10-producing, tolerogenic dendritic cells.
Tuettenberg A; Fondel S; Steinbrink K; Enk AH; Jonuleit H
Exp Dermatol; 2010 Jan; 19(1):44-53. PubMed ID: 19889024
[TBL] [Abstract][Full Text] [Related]
16. Co-expression of CD40L with CD70 or OX40L increases B-cell viability and antitumor efficacy.
Shin CA; Cho HW; Shin AR; Sohn HJ; Cho HI; Kim TG
Oncotarget; 2016 Jul; 7(29):46173-46186. PubMed ID: 27323820
[TBL] [Abstract][Full Text] [Related]
17. K562-Derived Whole-Cell Vaccine Enhances Antitumor Responses of CAR-Redirected Virus-Specific Cytotoxic T Lymphocytes In Vivo.
Caruana I; Weber G; Ballard BC; Wood MS; Savoldo B; Dotti G
Clin Cancer Res; 2015 Jul; 21(13):2952-62. PubMed ID: 25691731
[TBL] [Abstract][Full Text] [Related]
18. Autologous antileukemic immune response induced by chronic lymphocytic leukemia B cells expressing the CD40 ligand and interleukin 2 transgenes.
Takahashi S; Rousseau RF; Yotnda P; Mei Z; Dotti G; Rill D; Hurwitz R; Marini F; Andreeff M; Brenner MK
Hum Gene Ther; 2001 Apr; 12(6):659-70. PubMed ID: 11426465
[TBL] [Abstract][Full Text] [Related]
19. Preferential expression of B7.2 (CD86), but not B7.1 (CD80), on B cells induced by CD40/CD40L interaction is essential for anti-DNA autoantibody production in patients with systemic lupus erythematosus.
Nagafuchi H; Shimoyama Y; Kashiwakura J; Takeno M; Sakane T; Suzuki N
Clin Exp Rheumatol; 2003; 21(1):71-7. PubMed ID: 12673892
[TBL] [Abstract][Full Text] [Related]
20. Proinflammatory cytokines and CD40 ligand enhance cross-presentation and cross-priming capability of human dendritic cells internalizing apoptotic cancer cells.
Hoffmann TK; Meidenbauer N; Müller-Berghaus J; Storkus WJ; Whiteside TL
J Immunother; 2001; 24(2):162-71. PubMed ID: 11265774
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
